Skip to main content
. Author manuscript; available in PMC: 2013 Dec 1.
Published in final edited form as: J Thromb Haemost. 2012 Dec;10(12):2563–2572. doi: 10.1111/jth.12017

Fig 5.

Fig 5

Megakaryocytes that overexpress peroxisome proliferator-activated receptor-γ (PPARγ) respond to rosiglitazone by increasing platelet production. (A) Live culture representative images depict green fluorescent protein (GFP)-transduced (left) or PPARγ-transduced (right) Meg-01 megakaryocytes. Cultures were left untreated (top) or treated with 10 μM rosiglitazone. White arrows highlight cytoplasmic processes; × 40 objective. (B) GFP-transduced (gray) or PPARγ-transduced (black) Dami megakaryocytes were untreated (dashed line) or treated with 10 μM rosiglitazone (solid line) for the indicated times. GFP-positive platelet-like particles were quantified with flow cytometry, and normalized to total megakaryocytes. (C) Normalized platelet-like particle counts from 72-h cultures are plotted and analyzed with a two-way ANOVA.***P < 0.001. NS, not significant; Rosi, rosiglitazone.